While the drug combo did meet the first goal of increasing progression-free survival, it failed to prolong overall survival beyond what is normal for patients on chemotherapy without Erbitux.
But while the scale of improvements in child survival is immense, globally we are still far short of achieving Millennium Development Goal (MDG) 4 to reduce child mortality by two-thirds.